About Soleno Therapeutics, Inc.
https://soleno.lifeSoleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program.
CEO
Anish Bhatnagar
Compensation Summary
(Year 2020)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-08-26 | Reverse | 1:15 |
| 2017-10-06 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 3 of 113
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Guggenheim
Buy
HC Wainwright & Co.
Buy
Stifel
Buy
Laidlaw & Co.
Buy
Oppenheimer
Outperform
Baird
Outperform
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
FMR LLC
Shares:8M
Value:$339.67M
JANUS HENDERSON GROUP PLC
Shares:6.06M
Value:$257.15M
PRICE T ROWE ASSOCIATES INC /MD/
Shares:3.9M
Value:$165.72M
Summary
Showing Top 3 of 252
About Soleno Therapeutics, Inc.
https://soleno.lifeSoleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $66.02M ▲ | $42.77M ▲ | $26.01M ▲ | 39.4% ▲ | $0.49 ▲ | $27.91M ▲ |
| Q2-2025 | $32.66M ▲ | $38.49M ▼ | $-4.71M ▲ | -14.42% ▼ | $-0.09 ▲ | $-2.83M ▲ |
| Q1-2025 | $0 | $45.74M ▼ | $-43.77M ▲ | 0% | $-0.95 ▲ | $-41.91M ▲ |
| Q4-2024 | $0 | $59.12M ▼ | $-55.98M ▲ | 0% | $-1.27 ▲ | $-49.48M ▲ |
| Q3-2024 | $0 | $80.21M | $-76.62M | 0% | $-1.83 | $-78.83M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $498.93M ▲ | $599.89M ▲ | $105.09M ▲ | $494.81M ▲ |
| Q2-2025 | $286.84M ▼ | $332.31M ▲ | $92.17M ▲ | $240.14M ▲ |
| Q1-2025 | $289.95M ▼ | $318.09M ▼ | $85.83M ▼ | $232.26M ▼ |
| Q4-2024 | $291.44M ▲ | $330.97M ▲ | $85.86M ▲ | $245.11M ▼ |
| Q3-2024 | $256.78M | $296.71M | $32.01M | $264.7M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $26.01M ▲ | $43.63M ▲ | $-91.44M ▼ | $217.98M ▲ | $170.16M ▲ | $43.63M ▲ |
| Q2-2025 | $-4.71M ▲ | $-12.61M ▲ | $-7.92M ▼ | $15.69M ▲ | $-4.83M ▲ | $-12.62M ▲ |
| Q1-2025 | $-43.77M ▲ | $-32.75M ▼ | $22.94M ▲ | $3.22M ▼ | $-6.6M ▼ | $-32.76M ▼ |
| Q4-2024 | $-55.98M ▲ | $-23.99M ▼ | $6.44M ▲ | $57.06M ▲ | $39.52M ▲ | $-24M ▼ |
| Q3-2024 | $-76.62M | $-14.93M | $4.04M | $2.27M | $-8.61M | $-15.12M |
CEO
Anish Bhatnagar
Compensation Summary
(Year 2020)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-08-26 | Reverse | 1:15 |
| 2017-10-06 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 3 of 113
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Guggenheim
Buy
HC Wainwright & Co.
Buy
Stifel
Buy
Laidlaw & Co.
Buy
Oppenheimer
Outperform
Baird
Outperform
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
FMR LLC
Shares:8M
Value:$339.67M
JANUS HENDERSON GROUP PLC
Shares:6.06M
Value:$257.15M
PRICE T ROWE ASSOCIATES INC /MD/
Shares:3.9M
Value:$165.72M
Summary
Showing Top 3 of 252